Tatiana Kovalenko

Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial

D. Karpf, V. Breinholt, P. Hofman, 2021, The Journal of clinical endocrinology and metabolism.

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

M. Wheeler, N. Dixit, W. Tamborlane, 2023, The Lancet Diabetes & Endocrinology.

OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial

D. Karpf, J. Leff, P. Hofman, 2019, Journal of the Endocrine Society.